• LAST PRICE
    3.9600
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    3.8200/ 4
  • Ask / Lots
    4.0000/ 30
  • Open / Previous Close
    0.0000 / 3.9600
  • Day Range
    ---
  • 52 Week Range
    Low 3.1300
    High 8.4000
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 3.89
TimeVolumeCAPR
09:32 ET118553.82
09:34 ET4613.82
09:38 ET6003.8699
09:39 ET1003.82
09:41 ET124003.8401
09:45 ET1003.8454
09:48 ET1123.855
09:50 ET2543.8514
09:52 ET5003.86
09:57 ET6003.86
09:59 ET40003.8699
10:01 ET1003.8516
10:03 ET26453.84
10:06 ET20503.9071
10:08 ET1003.8801
10:10 ET4503.89
10:14 ET3003.89
10:15 ET2003.9
10:26 ET9813.92
10:30 ET2003.9014
10:33 ET4003.9
10:37 ET30003.91
10:42 ET6253.9001
10:46 ET5003.9013
10:48 ET1003.9
10:50 ET5003.9
10:57 ET6403.9058
11:00 ET5003.9107
11:02 ET44503.9499
11:06 ET2263.96
11:08 ET1003.96
11:09 ET2003.96
11:13 ET11983.95
11:18 ET10003.96
11:20 ET2003.96
11:26 ET4003.9775
11:27 ET5093.9641
11:29 ET2003.96
11:42 ET19033.95
11:44 ET1003.95
11:51 ET26003.97
11:54 ET5003.97
11:58 ET15003.97
12:03 ET36993.96
12:05 ET2883.977
12:09 ET1003.97
12:20 ET5003.98
12:34 ET1003.98
12:38 ET2003.96
12:39 ET10003.98
12:43 ET1003.9626
12:45 ET1003.96
12:52 ET1183.9616
12:56 ET22504
12:59 ET10004.0084
01:01 ET19304.0002
01:03 ET2003.99
01:08 ET5003.9801
01:12 ET2503.9987
01:14 ET20003.9827
01:15 ET6003.99
01:21 ET44004
01:26 ET4004
01:39 ET75053.98
01:42 ET1003.9999
01:44 ET113274.02
01:46 ET9004.01
01:48 ET45104
01:50 ET5994.02
01:57 ET3004.01
02:04 ET5003.99
02:06 ET21893.99
02:15 ET43904.01
02:18 ET13994.02
02:26 ET5004.0213
02:27 ET16004.02
02:29 ET17004.025
02:33 ET4894.04
02:36 ET17584
02:38 ET8344.02
02:40 ET2004
02:44 ET2004
02:45 ET7004.02
02:49 ET1004.02
02:51 ET52964
02:54 ET6374
02:56 ET92833.99
02:58 ET10004.02
03:00 ET11004.0092
03:02 ET1003.99
03:07 ET5003.99
03:12 ET10004.0099
03:14 ET2003.98
03:20 ET4003.99
03:30 ET7354.02
03:34 ET3004.01
03:38 ET11004.005
03:45 ET11903.9816
03:48 ET10003.97
03:50 ET22993.96
03:56 ET5293.99
03:57 ET6253.9838
03:59 ET73293.96
Data delayed at least 15 minutes.

Oct 11, 2021

Sep 27, 2021

Sep 24, 2021

1:14PM ET on Friday Sep 24, 2021 by MT Newswires

1:12PM ET on Friday Sep 24, 2021 by Thomson Reuters

11:39AM ET on Friday Sep 24, 2021 by Thomson Reuters
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCAPR
Capricor Therapeutics Inc
91.2M
-4.7x
---
United StatesAIM
AIM ImmunoTech Inc
92.8M
-5.1x
---
United StatesHDVY
Health Discovery Corp
90.2M
-33.2x
---
United StatesAIMD
Ainos Inc
92.6M
-17.3x
---
United StatesTPST
Tempest Therapeutics Inc
93.6M
-0.6x
---
United StatesMTCR
Metacrine, Inc.
93.9M
-1.8x
---
As of 2021-10-20

Company Information

Capricor Therapeutics, Inc. is a biotechnology company. The Company is focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of diseases. It consists of cell therapy program, including CAP-1002 with Duchenne muscular dystrophy program and CAP-1002 with COVID-19 (SARS-CoV-2) program. It also includes exosomes program, such as exosome-based vaccines, exosome-based therapeutics and CDC-Derived Exosomes (CAP-2003). Duchenne muscular dystrophy program has completed HOPE-2, a Phase II clinical trial in the United States with its product candidate.CAP-1002 is a cardiac cell derived therapy used to treat patients with late-stage Duchenne muscular dystrophy. The Company has received the United States Food and Drug Administration (FDA) acceptance of its investigational new drug (IND) application for a clinical study of CAP-1002 in patients with severe or critical COVID-19.

Contact Information

Headquarters
8840 Wilshire Blvd Fl 2BEVERLY HILLS, CA, United States 90211-2606
Phone
310-358-3200
Fax
302-655-5049

Executives

Independent Executive Chairman of the Board
Frank Litvack
President, Chief Executive Officer, Director
Linda Marban
Chief Financial Officer, Principal Accounting Officer
Anthony Bergmann
Executive Vice President, General Counsel
Karen Krasney
Vice President - Regulatory Affairs and Drug Development
Thomas Copmann

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$91.2M
Revenue (TTM)
$319.6K
Shares Outstanding
23.0M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
6.36
EPS
$-0.84
Book Value
$1.37
P/E Ratio
-4.7x
Price/Sales (TTM)
285.3
Price/Cash Flow (TTM)
---
Operating Margin
-5,638.70%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.